{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:16:45Z","timestamp":1783664205018,"version":"3.55.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Advanced or metastatic non-small cell lung cancer (NSCLC) is associated with significant symptom burden. It is important to understand the impact of these disease-and treatment-related symptoms on patients\u2019 daily lives and explore from a patient perspective what constitutes a meaningful change in NSCLC symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patient experience of advanced or metastatic NSCLC was explored in this prospective, non-interventional qualitative research study recruiting patients from the United States (US). Interviews were conducted to explore the most important symptoms, daily life impacts, and patients\u2019 perspectives of what constitutes meaningful change when considering their current symptoms versus 6\u201312\u2009months prior, based on the Patient Global Impression of Severity (PGI-S) and Patient Global Impression of Change (PGI-C) items.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between February and April 2022, 19 US-based patients with Stage IV NSCLC were recruited; 95% were female, 63% were White, 79% had been diagnosed &amp;gt;1\u2009year prior, and 63% were receiving targeted therapy. Over half the patients indicated their most important symptoms were fatigue, shortness of breath, and cough. Patient differentiation between whether symptoms were disease- or treatment-related lacked concordance, and often patients were unable to distinguish the two. The most frequently mentioned impacts of these symptoms on patients\u2019 daily lives were difficulty walking, sleep disturbance, anxiety\/depression, impact on relationships, and difficulty doing daily tasks. Most patients considered a one-point change on the PGI-S or PGI-C to be meaningful based on rating their symptom severity at the time of the interview compared with 6\u201312\u2009months before the interview.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on their own symptom experience, patients with advanced or metastatic NSCLC indicated a one-point threshold for meaningful change, whether improvement or worsening. This suggests a one-point change on the PGI-S or PGI-C may be a potential anchor for patient-reported outcome (PRO) endpoints used in clinical trials. It is important to use PRO instruments that capture the symptoms and impacts identified as most important to patients. These findings highlight the importance of using qualitative methods to assess disease-related symptoms, treatment-related side effects, and the impacts on daily life for patients with advanced or metastatic NSCLC, underscoring how qualitative assessments can complement quantitative PRO instruments for evaluating clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyg.2023.1217793","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T15:23:15Z","timestamp":1694186595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Perspectives of patients with advanced or metastatic non-small cell lung cancer on symptoms, impacts on daily activities, and thresholds for meaningful change: a qualitative research study"],"prefix":"10.3389","volume":"14","author":[{"given":"Anna","family":"Cardellino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasee","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Roborel de Climens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Taiyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Stojadinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","article-title":"Epidemiology of Stage III lung cancer: frequency, diagnostic characteristics, and survival","volume":"10","author":"Casal-Mouri\u00f1o","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jtcvs.2017.08.138","article-title":"The eighth edition TNM stage classification for lung cancer: what does it mean on main street?","volume":"155","author":"Detterbeck","year":"2018","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"770423","DOI":"10.3389\/fneur.2021.770423","article-title":"A patient-centered evaluation of meaningful change on the 32-item motor function measure in spinal muscular atrophy using qualitative and quantitative data","volume":"12","author":"Duong","year":"2021","journal-title":"Front. Neurol."},{"key":"ref4","article-title":"Guidance for industry, patient-reported outcome measures: use in medical product development to support labeling claims","year":"2009"},{"key":"ref5","article-title":"Patient-focused drug development guidance public workshop: methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments","year":"2018"},{"key":"ref6","article-title":"Public workshop on patient-focused drug development: guidance 4\u2014incorporating clinical outcome assessments into endpoints for regulatory decision making","year":"2019"},{"key":"ref7","article-title":"Core patient-reported outcomes in cancer clinical trials: guidance for industry","year":"2021"},{"key":"ref8","article-title":"FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making","year":"2022"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jval.2018.09.2842","article-title":"A review of patient-reported outcomes labeling for oncology drugs approved by the FDA and the EMA (2012\u20132016)","volume":"22","author":"Gnanasakthy","year":"2019","journal-title":"Value Health"},{"key":"ref10","first-page":"76","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for Stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update","volume":"39","author":"Hanna","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.lungcan.2013.03.008","article-title":"Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany","volume":"81","author":"Iyer","year":"2013","journal-title":"Lung Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.cllc.2017.02.008","article-title":"Emotional problems, quality of life, and symptom burden in patients with lung cancer","volume":"18","author":"Morrison","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12955-018-1055-z","article-title":"Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review","volume":"16","author":"Ousmen","year":"2018","journal-title":"Health Qual. Life Outcomes"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","article-title":"Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2\u2014assessing respondent understanding","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40744-021-00292-1","article-title":"Patient experience with fatigue and qualitative interview-based evidence of content validation of the FACIT-fatigue in systemic lupus erythematosus","volume":"8","author":"Raymond","year":"2021","journal-title":"Rheumatol. Ther."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.22.00825","article-title":"Therapy for Stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline","volume":"40","author":"Singh","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s13142-015-0345-9","article-title":"News from the NIH: person-centered outcomes measurement: NIH-supported measurement systems to evaluate self-assessed health, functional performance, and symptomatic toxicity","volume":"6","author":"Smith","year":"2016","journal-title":"Transl. Behav. Med."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"968272","DOI":"10.3389\/fmed.2022.968272","article-title":"A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020","volume":"9","author":"Teixeira","year":"2022","journal-title":"Front. Med."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/cncr.21398","article-title":"Symptoms in patients with lung carcinoma","volume":"104","author":"Tishelman","year":"2005","journal-title":"Cancer"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"103747","DOI":"10.1016\/j.critrevonc.2022.103747","article-title":"Assessing the methodological quality of quality-of-life analyses in first-line non-small cell lung cancer trials: a systematic review","volume":"176","author":"Waisberg","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"100298","DOI":"10.1016\/j.jtocrr.2022.100298","article-title":"Non-small cell lung cancer symptom assessment questionnaire (NSCLC-SAQ): measurement properties and estimated clinically meaningful thresholds from a phase 3 study","volume":"3","author":"Williams","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/JTO.0b013e3182397b3e","article-title":"Quality of life and symptom burden among long-term lung cancer survivors","volume":"7","author":"Yang","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cllc.2011.03.033","article-title":"A brief symptom index for advanced lung cancer","volume":"13","author":"Yount","year":"2012","journal-title":"Clin. Lung Cancer"}],"container-title":["Frontiers in Psychology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyg.2023.1217793\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T18:47:27Z","timestamp":1718131647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyg.2023.1217793\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":24,"alternative-id":["10.3389\/fpsyg.2023.1217793"],"URL":"https:\/\/doi.org\/10.3389\/fpsyg.2023.1217793","relation":{},"ISSN":["1664-1078"],"issn-type":[{"value":"1664-1078","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"article-number":"1217793"}}